시장보고서

상품코드

1609604

항체 수탁제조 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 유래별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End-use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 11월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항체 수탁제조 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 항체 수탁제조 시장 규모는 2025년부터 2030년까지 10.1%의 CAGR을 기록하며 2030년까지 317억 6,000만 달러에 달할 것으로 예상됩니다.

치료용 항체 생산에 대한 수요 증가는 예측 기간 동안 시장 성장을 촉진하는 주요 요인입니다. 항체는 비정상적인 세포를 정확하게 표적으로 삼는 주요 바이오의약품입니다. 따라서 많은 바이오 제약 회사들이 암, 관절염, 류마티스성 심장병과 같은 만성질환을 치료하기 위해 첨단 항체 개발에 주력하고 있으며, COVID-19의 영향은 COVID-19 환자 치료에 사용되는 단클론항체 치료제의 적용으로 시장 성장을 촉진하고 있습니다.

주요 기업들이 항체 생산을 위한 R&D 예산을 대폭 늘리면서 시장 성장에 힘을 보태고 있습니다. 현재 진행 중인 COVID-19와의 싸움에서 단클론항체(mAb) 치료는 효과적인 치료법으로 입증되고 있습니다. 이 치료의 목적은 입원을 예방하고, 바이러스 양을 감소시키며, 증상의 심각성을 최소화하는 것입니다.

COVID-19가 유행할 때에도 바이오 제약 기업의 공급망은 전 세계적으로 거의 영향을 받지 않고 견고하게 유지되었습니다. 마찬가지로 항체 위탁 생산 업체들도 COVID-19 백신 및 치료제 관련 치료에 사용되는 항체 생산에 대한 수요 증가를 관찰하고 있습니다. 따라서 항체 수탁제조 시장에는 향후 많은 비즈니스 기회가 있습니다. 예를 들어, 2021년 12월 삼성바이오로직스와 아스트라제네카(AstraZeneca)는 COVID-19의 잠재적 치료제로 개발 중인 바이너리 항체의 합병체인 Evusheld를 생산하기 위한 계약을 체결하였습니다.

CMO의 성장은 바이오 제약 산업이 제공하는 기회에 따라 크게 좌우됩니다. 생명과학 분야에 대한 벤처 캐피털 투자의 확대와 견조한 성장세는 시장을 주도할 것으로 예상되는 두 가지 중요한 기회입니다. 예를 들어, FUJIFILM Diosynth Biotechnologies는 2022년 노스캐롤라이나 주에서 사업 확장을 발표했습니다. 이 사업 확장을 통해 회사는 2024년까지 연구원과 과학자를 포함한 숙련된 직책을 늘리고 강력한 상업적 프로세스를 창출할 계획입니다.

항체 수탁제조 시장 보고서 하이라이트

단클론항체 기반 항체 수탁제조는 생물학적 제제 개발을 위한 포유류 발현 시스템의 높은 침투로 인해 2024년 약 76.42%의 가장 큰 시장 점유율을 차지했습니다.
이 시장에서 제공되는 소스를 기반으로 포유류 부문은 더 안정적이고 견고하며 상대적으로 성숙한 기술로 간주되어 2024년 57.52%의 가장 큰 점유율을 차지했습니다.
아시아태평양은 인도, 한국, 중국 등 신흥 경제 국가들이 경쟁을 유지하기 위해 개발을 도입함에 따라 예측 기간 동안 가장 빠르게 성장하는 지역 시장이 될 것으로 예상됩니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국
- 쿠웨이트

제8장 경쟁 구도

진출 기업
전략 매핑
기업 시장 상황 분석, 2024년(기업 히트맵 분석)
기업 개요
- Lonza
- Samsung Biologics
- WuXi Biologics
- Charles River Laboratories
- FUJIFILM Holdings Corporation
- Boehringer Ingelheim GmbH
- AGC Biologics
- Cytovance Biologics, Inc.
- EMERGENT
- Thermo Fisher Scientific, Inc.
- Catalent, Inc
- Laboratory Corporation of America Holdings

ksm 24.12.26

Antibodies Contract Manufacturing Market Growth & Trends:

The global antibody contract manufacturing market size is expected to reach USD 31.76 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Report Highlights:

Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 76.42% in 2024, owing to the high penetration of mammalian expression systems for biologics development
Based on the source offered in this market, the mammalian segment contributed the largest share of 57.52% in 2024, as they are considered a more reliable, robust, and relatively mature technology
Asia Pacific is expected to emerge as the fastest-growing regional market during forecast period, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
  - 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
  - 1.7.2.1. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Contract Manufacturing Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.2. Market Restraints Analysis
- 3.2.3. Industry Challenges
3.3. Market Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Analysis

Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Product Movement Analysis
4.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
4.4. Monoclonal Antibodies
- 4.4.1. Monoclonal Antibodies Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
4.5. Polyclonal Antibodies
- 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

5.1. Segment Dashboard
5.2. Source Movement Analysis
5.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
5.4. Mammalian Source
- 5.4.1. Mammalian Source Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Microbial
- 5.5.1. Microbial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

6.1. Segment Dashboard
6.2. End Use Movement Analysis
6.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
6.4. Biopharmaceutical Companies
- 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Research Laboratories
- 6.5.1. Research Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis

7.1. Regional market share analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. North America
- 7.3.1. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Landscape
  - 7.3.2.4. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Landscape
  - 7.3.3.4. Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Landscape
  - 7.3.4.4. Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Europe
- 7.4.1. Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Landscape
  - 7.4.2.4. UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Landscape
  - 7.4.3.4. Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Landscape
  - 7.4.4.4. France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Competitive Scenario
  - 7.4.5.3. Regulatory Landscape
  - 7.4.5.4. Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Competitive Scenario
  - 7.4.6.3. Regulatory Landscape
  - 7.4.6.4. Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Denmark
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Competitive Scenario
  - 7.4.7.3. Regulatory Landscape
  - 7.4.7.4. Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.8. Sweden
  - 7.4.8.1. Key Country Dynamics
  - 7.4.8.2. Competitive Scenario
  - 7.4.8.3. Regulatory Landscape
  - 7.4.8.4. Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key Country Dynamics
  - 7.4.9.2. Competitive Scenario
  - 7.4.9.3. Regulatory Landscape
  - 7.4.9.4. Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Landscape
  - 7.5.2.4. China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Japan
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Landscape
  - 7.5.3.4. Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Landscape
  - 7.5.4.4. India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Landscape
  - 7.5.5.4. South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Australia
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Landscape
  - 7.5.6.4. Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Thailand
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Landscape
  - 7.5.7.4. Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Latin America
- 7.6.1. Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Landscape
  - 7.6.2.4. Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Landscape
  - 7.6.3.4. Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Middle East and Africa
- 7.7.1. Middle East and Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Landscape
  - 7.7.2.4. Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Landscape
  - 7.7.3.4. UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. South Africa
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Competitive Scenario
  - 7.7.4.3. Regulatory Landscape
  - 7.7.4.4. South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key Country Dynamics
  - 7.7.5.2. Competitive Scenario
  - 7.7.5.3. Regulatory Landscape
  - 7.7.5.4. Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
8.4. Company Profiles
- 8.4.1. Lonza
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Service Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Samsung Biologics
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Service Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. WuXi Biologics
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Service Benchmarking
- 8.4.4. Charles River Laboratories
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Service Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. FUJIFILM Holdings Corporation
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Service Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Boehringer Ingelheim GmbH
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Service Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. AGC Biologics
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Service Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Cytovance Biologics, Inc.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Service Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. EMERGENT
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Service Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Thermo Fisher Scientific, Inc.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Service Benchmarking
  - 8.4.10.4. Strategic Initiatives
  - 8.4.10.5. Strategic Initiatives
- 8.4.11. Catalent, Inc
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Service Benchmarking
  - 8.4.11.4. Strategic Initiatives
- 8.4.12. Laboratory Corporation of America Holdings
  - 8.4.12.1. Participant's Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Service Benchmarking
  - 8.4.12.4. Strategic Initiatives

항체 수탁제조 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 유래별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End-use, By Region, And Segment Forecasts, 2025 - 2030

항체 수탁제조 시장 성장 및 동향:

항체 수탁제조 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항체 수탁제조 시장 변수, 동향, 범위

제4장 항체 수탁제조 시장 : 제품 추정·동향 분석

제5장 유래 비즈니스 분석

제6장 최종 용도 비즈니스 분석

제7장 항체 수탁제조 시장 : 지역 추정·동향 분석